Novavax, Inc. (NVAX) News
Filter NVAX News Items
NVAX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NVAX News Highlights
- NVAX's 30 day story count now stands at 8.
- Over the past 15 days, the trend for NVAX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about NVAX are DRUG, NVX and EYE.
Latest NVAX News From Around the Web
Below are the latest news stories about NOVAVAX INC that investors may wish to consider to help them evaluate NVAX as an investment opportunity.
Smart Shorts: 7 Meme Stocks to Bet Against in 2024These seven meme stocks have surged as speculators declare "the coast is clear," but a big reversal for each of them may be forthcoming. |
3 Heavily Shorted Stocks That Still Won’t See a SqueezeThese are the heavily shorted stocks to avoid as they are likely to continue trending lower on the back of very weak fundamentals. |
Is Novavax Stock A Buy On Its Covid Vaccine Launch Spree?Novavax stock jumped this month as the company launched its updated Covid shot abroad. Is NVAX stock a buy or a sell right now? |
Owning 48% shares,institutional owners seem interested in Novavax, Inc. (NASDAQ:NVAX),Key Insights Significantly high institutional ownership implies Novavax's stock price is sensitive to their trading... |
3 Meme Stocks That Could Fade Away in 2024These are the meme stocks to avoid or sell as they have extremely weak fundamentals and are unlikely to recover from a financial perspective. |
Novavax's Updated COVID-19 Vaccine Receives Emergency Use Authorization in TaiwanNovavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the Taiwan Food and Drug Administration has granted emergency use authorization for Nuvaxovid™ XBB.1.5 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601) for active immunization to prevent COVID-19 in individuals aged 12 and older. |
UPDATE 2-US CDC says there's urgent need to increase respiratory vaccine coverageThe U.S. Centers for Disease Control and Prevention (CDC) on Thursday issued an alert urging healthcare providers to increase immunization coverage for influenza, COVID-19 and respiratory syncytial virus (RSV). The health regulator said that low vaccination rates, coupled with ongoing increases in respiratory disease activity, could lead to more severe disease and increased healthcare capacity strain in the coming weeks. Healthcare providers should recommend antiviral medications for influenza and COVID-19 for all eligible patients, especially older adults and people with certain underlying medical condition, the CDC said. |
Canadians Can Help Protect Loved Ones as We Head into the Holiday SeasonNovavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced the launch of Choose to Protect™, a campaign to educate the public about the importance of COVID-19 vaccination and COVID-19 vaccines. Since 2020, COVID-19 has become one of the leading causes of death in Canada.i,ii The campaign will feature resources in both English and French. |
UPDATE 1-Health Canada authorizes Novavax's updated COVID shot for OmicronNovavax said on Tuesday that Health Canada had authorized its updated COVID-19 vaccine, targeting the Omicron subvariant XBB.1.5, in individuals aged 12 years and older. Last month, WHO granted emergency-use authorization to the vaccine, which targets a descendant of the XBB lineage of the coronavirus that was globally predominant earlier this year. The U.S. Food and Drug Administration and the European Commission authorized the use of the updated vaccine in October. |
Novavax's Updated COVID-19 Vaccine Now Authorized in CanadaNovavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that Health Canada has granted expanded authorization for Nuvaxovid™ XBB.1.5 Vaccine (Recombinant protein, Adjuvanted) (NVX-CoV2601) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals aged 12 and older. The Public Health Agency of Canada's National Advisory Committee on Immunization recommended XBB COVID-19 vaccines that target more recent, imm |